Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9BUB4

UPID:
ADAT1_HUMAN

ALTERNATIVE NAMES:
tRNA-specific adenosine-37 deaminase

ALTERNATIVE UPACC:
Q9BUB4; Q9NVB7; Q9UNG3

BACKGROUND:
tRNA-specific adenosine deaminase 1, identified by its unique activity of converting adenosine-37 to inosine in tRNA-Ala, is pivotal for the fidelity of protein synthesis. This enzyme's specificity ensures that proteins are synthesized correctly, a process essential for cellular function and viability.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of tRNA-specific adenosine deaminase 1 holds promise for uncovering new therapeutic avenues. Given its critical role in tRNA modification and protein synthesis, targeting this enzyme could lead to innovative treatments for diseases where protein synthesis is disrupted.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.